Novartis, Novo sue Bayer over patent

Novartis and Novo Nordisk are ganging up on Bayer, alleging that the German company's hemophilia treatment Kogenate infringes on one of their joint patents. In a statement, Bayer said it would "vigorously defend itself" against the complaint, and that it doesn't believe it has overstepped the bounds of any patents. The company's stock fell on the news. Meanwhile, other news reports said the suit, filed in federal court in Texas, names Wyeth as well. The New Jersey-based firm has not yet commented.

- see Bayer's release
- read the article at CNN Money
- check out reports of the Wyeth connection at CNN Money

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.